Phase III Randomized Trial of Thalidomide/Dexamethasone Versus Vincristine+Adriamycin+Dexamethasone (VAD)
Status:
Terminated
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
Investigators planned to accrue 176 participants, to compare the response rate, overall
response rate and survival of patients with multiple myeloma (MM) when randomized to two
regimens (thalidomide+Dexamethasone versus Vincristine+Adriamycin+Dexamethasone).
Investigators also planned to test if treatment with zoledronate immediately prior to
chemotherapy results in an enhanced response to treatment (i.e. increase in complete response
rates).
Phase:
Phase 3
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute